Current Status of Newer Carbapenems

被引:50
作者
Bassetti, Matteo
Nicolini, Laura
Esposito, Silvano
Righi, Elda
Viscoli, Claudio
机构
[1] San Martino Univ Hosp, Div Infect Dis, Genoa, Italy
[2] Univ Genoa, Genoa, Italy
关键词
Carbapenems; imipenem; meropenem; ertapenem; biapenem; panipenem; tebipenem pivoxil; doripenem; IN-VITRO ACTIVITY; RESISTANT STAPHYLOCOCCUS-AUREUS; URINARY-TRACT-INFECTIONS; VENTILATOR-ASSOCIATED PNEUMONIA; COMPLICATED INTRAABDOMINAL INFECTIONS; APPROPRIATE ORAL-THERAPY; DOUBLE-BLIND MULTICENTER; METALLO-BETA-LACTAMASES; IMPAIRED RENAL-FUNCTION; GRAM-NEGATIVE BACILLI;
D O I
10.2174/092986709787458498
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Objectives: Beta-lactam antibiotics represent the most commonly prescribed antibacterial agents. Since many bacteria have developed resistance to older agents, new beta-lactams have been introduced constantly. In the late 1970s, a new class of exceptionally broad-spectrum beta-lactams, the carbapenems, was identified. The carbapenems, such as the most popular imipenem and meropenem, have the widest spectra of antibacterial activity of all the beta-lactams and provide excellent coverage of many gram-negative and gram-positive aerobic and anaerobic bacteria. Despite the wide antibacterial spectrum, the carbapenems globally lack activity against Enterococcus faecium, methicillin-resistant Staphylococcus aureus (MRSA) and Stenotrophomonas maltophilia. Methods: We reviewed the principal characteristics of the novel carbapenems and their clinical implications. Results and conclusions: We included in our review: ertapenem, biapenem, panipenem, doripenem, tebipenem pivoxil and tomopenem.
引用
收藏
页码:564 / 575
页数:12
相关论文
共 141 条
[1]
IN-VITRO ACTIVITY OF BIAPENEM (L-627), A NEW CARBAPENEM, AGAINST ANAEROBES [J].
ALDRIDGE, KE ;
MORICE, N ;
SCHIRO, DD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :889-893
[2]
IN-VITRO ACTIVITY OF BIAPENEM AGAINST BETA-LACTAMASE-PRODUCING ENTEROBACTERIACEAE [J].
ALONSO, R ;
FDEZARANGUIZ, A ;
COLOM, K ;
MORLA, A ;
SUINAGA, E ;
UMARAN, A ;
CISTERNA, R .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1994, 13 (10) :820-822
[3]
A STANDARD NUMBERING SCHEME FOR THE CLASS-A BETA-LACTAMASES [J].
AMBLER, RP ;
COULSON, AFW ;
FRERE, JM ;
GHUYSEN, JM ;
JORIS, B ;
FORSMAN, M ;
LEVESQUE, RC ;
TIRABY, G ;
WALEY, SG .
BIOCHEMICAL JOURNAL, 1991, 276 :269-270
[4]
Doripenem [J].
Anderson, David Leif .
DRUGS OF TODAY, 2006, 42 (06) :399-404
[5]
[Anonymous], 47 ANN INT C ANT AG
[6]
SUSCEPTIBILITY OF 539 GRAM-POSITIVE AND GRAM-NEGATIVE ANAEROBES TO NEW AGENTS, INCLUDING RP59500, BIAPENEM, TROSPECTOMYCIN AND PIPERACILLIN TAZOBACTAM [J].
APPELBAUM, PC ;
SPANGLER, SK ;
JACOBS, MR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 (02) :223-231
[7]
Imipenem/cilastatin - An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections [J].
Balfour, JA ;
Bryson, HM ;
Brogden, RN .
DRUGS, 1996, 51 (01) :99-136
[8]
Novel β-lactam antibiotics and inhibitor combinations [J].
Bassetti, Matteo ;
Righi, Elda ;
Viscoli, Claudio .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (03) :285-296
[9]
Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum β-lactamase-producing organisms in an intensive care unit [J].
Bassetti, Matteo ;
Righi, Elda ;
Fasce, Roberta ;
Molinari, Maria Pia ;
Rosso, Raffaella ;
Di Biagio, Antonio ;
Mussap, Michele ;
Pallavicini, Franco Bobbio ;
Viscoli, Claudio .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (02) :433-435
[10]
Use of pharmacokinetic-pharmaco dynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem [J].
Bhavnani, SM ;
Hammel, JP ;
Cirincione, BB ;
Wikler, MA ;
Ambrose, PG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) :3944-3947